Middle East and Africa myositis treatment market is projected to register a CAGR of 5.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation
Middle East & Africa Myositis Treatment Market, By Type (Polymyositis, Dermatomyositis, Inclusion Body Myositis (IBM), Necrotizing Myopathy, Juvenile Myositis and Others), Treatment (Medication, Therapy and Supplements), End User (Hospitals, Therapy Centers, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and Rest of Middle East and Africa) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of Middle East and Africa myositis treatment market are:
- Presence of novel pipeline.
- Rising awareness about the disease.
Market Players
The key market players for Middle East and Africa myositis treatment market are listed below:
- Takeda Pharmaceutical Company Limited
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Pfizer Inc.
- Accord Healthcare
- Sandoz AG (A Subsidiary of Novartis AG)